Is Ramsay Health Care stock a buy right now?
Ramsay Health Care (ASX:RHC) offers a compelling perspective for Australian investors as of early May 2025, with its share price hovering around AU$34.29 and recent average daily trading volume exceeding 900,000 shares. The market has responded calmly to a leadership change, as incoming CEO Natalie Davis takes the helm amid strategic efficiency measures and ongoing investment in technology across its 500+ global healthcare facilities. Despite a challenging half-year result—driven largely by significant but non-recurring items—recent revenue growth of 5.7% year-over-year illustrates resilience in patient demand, particularly as private health insurance uptake rises in Australia and Europe. Technical signals are strongly constructive: all key moving averages indicate buy, and analyst sentiment points to above-average earnings and revenue projections ahead. While profit margins are compressed, market consensus among more than 32 national and international banks sets a target price near AU$44.60, reflecting growing confidence in a sector that remains fundamental to demographic and economic stability worldwide. For those seeking diversified healthcare exposure, Ramsay Health Care’s ongoing operational improvements and strong footing signal potential for steady longer-term gains, complemented by its continued commitment to dividend payouts.
- Largest private hospital operator in Australia and leading presence across Europe and UK.
- Diversified global operations with more than 500 facilities and 90,000 employees worldwide.
- Revenue growth sustained at 5.7% year-over-year, outpacing many sector peers.
- Significant recent investments in healthcare technology and operational efficiency.
- Consensus analyst forecast sees robust earnings and revenue improvement in coming years.
- High debt-to-equity ratio increases financial leverage and limits short-term flexibility.
- Profit margins compressed by recent one-off items and rising industry competition.
- What is Ramsay Health Care?
- How much is Ramsay Health Care stock?
- Our full analysis on Ramsay Health Care </b>stock
- How to buy Ramsay Health Care stock in Australia?
- Our 7 tips for buying Ramsay Health Care stock
- The latest news about Ramsay Health Care
- FAQ
Why trust HelloSafe?
At HelloSafe, our expert has been monitoring the performance of Ramsay Health Care for over three years. Each month, hundreds of thousands of Australians rely on us to break down market trends and highlight the best investment opportunities. Our analyses are provided for informational purposes only and do not constitute financial advice. In line with our ethical charter, we have never been, and will never be, paid by Ramsay Health Care.
What is Ramsay Health Care?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | Australian | Headquarters in Sydney; operates healthcare facilities globally. |
| 💼 Market | ASX (ASX:RHC) | Listed on the Australian Securities Exchange; a major healthcare sector constituent. |
| 🏛️ ISIN code | AU000000RHC8 | Unique global identifier for Ramsay Health Care's listed shares. |
| 👤 CEO | Natalie Davis (since Oct 2024) | New leadership presents an opportunity for strategic renewal and growth. |
| 🏢 Market cap | AU$7.92 billion | Reflects moderate size; significantly reduced after a substantial share price decline. |
| 📈 Revenue | AU$17.12 billion (TTM) | Continued top-line growth despite challenging market environment. |
| 💹 EBITDA | AU$1.53 billion (TTM) | Demonstrates strong underlying operating cash generation capabilities. |
| 📊 P/E Ratio (Price/Earnings) | 443.6 | Extremely high P/E signals low earnings and profit margin compression; raises valuation risk. |
How much is Ramsay Health Care stock?
The price of Ramsay Health Care stock is rising this week. As of today, RHC is trading at AU$34.29, up 1.81% over the past 24 hours and showing a gain for the week. The company’s market capitalisation stands at AU$7.92 billion, with an average 3-month trading volume of 845,300 shares. Ramsay Health Care currently trades at a P/E ratio of 443.60 and offers a dividend yield of 2.33%. With a beta of 0.54, the stock typically experiences less volatility than the broader market, providing a relatively stable option for investors in Australia seeking consistent performance.
Check out the best brokers in Australia!Compare brokersOur full analysis on Ramsay Health Care stock
After a rigorous review of Ramsay Health Care’s latest financial results and a thorough assessment of the share’s dynamics over the last three years, coupled with our proprietary synthesis of financial, technical, sector, and peer data, we find compelling signals emerging for Ramsay Health Care (ASX:RHC). Despite the turbulence experienced across global healthcare equities, Ramsay’s resilient top-line performance and forward-looking strategic shifts invite renewed scrutiny from investors seeking robust exposure to a sector defined by secular growth. So, why might Ramsay Health Care stock once again become a strategic entry point into the healthcare sector in 2025?
Recent Performance and Market Context
Ramsay Health Care has demonstrated remarkable stamina amidst sector-wide volatility. With the share price currently at AU$34.29, the stock has staged a notable bounce from its 52-week low of AU$31.66, albeit still well off its annual high of AU$51.81. The recent uptick (+1.81% daily change as of early May 2025) signals renewed market interest, especially as the broader ASX200 Healthcare segment has begun recovering from 2024’s drawdown. While Ramsay experienced a -32.74% correction over the past twelve months, this reset has arguably paved the way for value-oriented entry, as excess froth has dissipated.
Crucially, Ramsay’s latest half-year results (reported February 2025) showcased 5.7% revenue growth, even in the context of macro headwinds, with quarterly top-line figures remaining robust. Much of the reported net loss stemmed from non-recurring items, suggesting that the underlying business remains fundamentally sound. In tandem, rising demand for private healthcare—fueled by increased uptake of private health insurance—has underpinned operational resilience in Australia, Europe, and the UK.
- Appointment of Natalie Davis as the new Group CEO in October 2024, bringing fresh leadership and focus on operational excellence.
- Aggressive efforts to drive cost efficiencies and implement technology-led margin improvements.
- Stable dividend policies, providing investors with a 2.33% yield even during transitional phases.
In aggregate, Ramsay Health Care finds itself entering 2025 with renewed strategic clarity and, arguably, much-reduced downside risk at prevailing valuations.
Technical Analysis
A comprehensive technical review bolsters the case for Ramsay as a technically attractive proposition. As of early May 2025:
- The stock trades above its 5-, 10-, 20-, 50-, 100-, and 200-day simple moving averages. Each of these levels (ranging from AU$33.17 to AU$34.20) is triggering buy signals, indicating short- to medium-term momentum remains positively oriented.
- The Relative Strength Index (RSI) at 71.57 reflects increased buying interest, albeit approaching overbought territory—often a hallmark of a nascent trend rather than its exhaustion.
- The Moving Average Convergence Divergence (MACD) at 0.22 and the Average Directional Index (ADX) at 48.7 further confirm the presence of a strong underlying trend.
- The Commodity Channel Index (CCI) at 115.43 strengthens this thesis with another buy signal, and while Williams %R at 0 denotes overbought, such readings frequently precede periods of persistent upward moves, especially in defensive sectors.
Critical price levels merit attention:
- Strong support is established at AU$33.42 and more decisively at the 52-week low of AU$31.66.
- The immediate resistance sits at AU$34.29 (recent high), with the next test at AU$37.87 (200-day MA).
In sum, the technical backdrop suggests that Ramsay may be entering a favorable phase, with a potential for continued momentum if upcoming catalysts materialize.
Fundamental Analysis
The fundamental picture at Ramsay is a study in operational robustness, strategic adaptation, and latent upside:
- Revenue and Profitability: Trailing twelve-month revenue stands at a formidable AU$17.12 billion, with EBITDA at AU$1.53 billion. Despite net income being modest (AU$8 million), this reflects the impact of AU$263 million in non-recurring items; adjusting for these, the underlying profitability profile is far more resilient.
- Growth Trajectory: The company has consistently grown revenues at a low- to mid-single-digit rate, defying economic cyclicality—a testament to the essential nature of healthcare services in both developed and emerging markets.
- Valuation: While the headline Price-to-Earnings (P/E) ratio appears elevated (443.60), this is an anomaly of temporary margin compression. Far more instructive is Ramsay’s Price-to-Sales (P/S) multiple at 0.46 and Price-to-Book (P/B) at 1.73, each below sector medians and indicative of undervaluation relative to assets and revenues.
- Operational Leverage: Recent cost-reduction and efficiency initiatives, particularly in Australia, are poised to yield incremental margin gains. Ramsay’s scale and geographic reach (over 500 facilities and ~90,000 employees worldwide) anchor its durable competitive advantages.
- Brand and Market Share: In Australia, Ramsay is the unchallenged market leader in the private hospital space; across Europe and the UK, its reputation and network breadth confer market power difficult for new entrants to replicate.
With analyst consensus targeting earnings growth of 47.4% per annum and a 19.6% upside to the stock’s mean price target (AU$41.03), fundamentals appear to justify renewed investor interest.
Volume and Liquidity
Liquidity dynamics reinforce confidence in Ramsay’s valuation and tradability:
- The stock’s consistently high average daily trading volume—undergirded by a robust domestic and international shareholder base—signals sustained institutional participation and market confidence.
- While some float concentration is evident, it serves to promote price stability and resists excessive volatility, promoting dynamic yet orderly revaluations as catalysts unfold.
- Notably, current volume patterns are congruent with accumulation phases often observed prior to more decisive bullish moves.
Catalysts and Positive Outlook
A number of imminent and structural catalysts are positioned to drive Ramsay’s next phase of re-rating:
- Leadership Reset: The appointment of Natalie Davis as CEO (October 2024) marks a generational shift in management. Her track record in operational transformation and healthcare digitisation is already informing strategic priorities.
- Efficiency and Digital Innovation: Active investment in workflow automation, electronic health records, and AI-driven patient care management—especially in Australia and the UK—should translate into superior cost control and enhanced patient outcomes.
- Macro Updrafts: Ageing demographics, rising demand for elective surgeries, and heightened adoption of private health insurance in core markets all suggest structural volume increases ahead.
- Sustainability and ESG Commitments: Enhanced ESG disclosure, carbon-neutral facility targets, and an intensifying focus on ethical healthcare delivery are aligning Ramsay squarely with global investor priorities.
- Strategic Refocusing: Portfolio optimisation, potential divestitures of non-core assets, and further consolidation in key regions could further unlock value.
The convergence of these vectors supports an outlook of improving profitability, margin expansion, and ultimately, shareholder value accretion.
Investment Strategies
Ramsay’s current valuation profile and technical positioning offer a spectrum of entry strategies suited to various investor timeframes:
Short Term (Weeks to Months):
- The upward technical momentum, underpinned by universal moving average buy signals, makes Ramsay attractive for tactical positioning at or near current levels.
- The proximity to strong support (AU$33.42/AU$31.66) provides clear risk management markers.
- An entry ahead of the next scheduled earnings or strategic updates could capitalise on potential positive surprises.
Medium Term (6–12 Months):
- The stock appears poised for a retracement toward the AU$37.87 resistance and, if breached, the analyst target band of AU$41.03–AU$48.30.
- Improving financial performance as cost control measures take hold and non-recurring impacts subside may spark renewed upward momentum.
Long Term (12 Months and Beyond):
- Ramsay’s embedded defensiveness, global diversification, and scale uniquely position it to benefit from long-term sectoral tailwinds.
- For investors seeking compounders in the healthcare sector, establishing a position during periods of margin recovery arguably offers compelling asymmetric upside.
Across all horizons, the case for Ramsay is amplified when entering during technical consolidations or ahead of visible catalysts such as leadership announcements, earnings, or material operational wins.
Is it the Right Time to Buy Ramsay Health Care?
Summing up, Ramsay Health Care exemplifies the core traits associated with an attractive investment in 2025’s healthcare landscape: durable competitive positioning, improving operational metrics, and a technical backdrop suggestive of renewed momentum. At current price levels, the risk/reward profile stands out—recent downtrends have cleared much of the speculative excess, yet the stock trades at a discount to intrinsic value and consensus price targets.
- A return to consistent revenue growth even amid sector headwinds
- High conviction analyst forecasts for margin and earnings expansion
- Strong technical confirmatory signals suggesting a nascent bullish phase
- Management renewal and targeted efficiency drives likely to yield operational upside
- An attractive dividend yield supporting total return, despite the interim challenges
In an environment where quality defensive growth names are increasingly prized, Ramsay Health Care seems to represent an excellent opportunity for investors attuned to both technical and fundamental signals. While vigilance around debt and margin pressures remains warranted, the stock may be poised to enter a new upward cycle—with the prospect of robust returns for those prepared to look through temporary headwinds. As the next catalysts approach, Ramsay Health Care deserves to be firmly on the radar of investors searching for high-conviction exposure to global healthcare innovation and stability.
How to buy Ramsay Health Care stock in Australia?
Buying Ramsay Health Care (ASX:RHC) shares online is easier and safer than ever, thanks to Australia’s well-regulated brokers. Whether you want to directly own RHC stock (spot buying) or prefer to trade price movements using Contracts for Difference (CFDs), both methods can be accessed securely via reputable online platforms. Spot buying is best for long-term investors, while CFDs suit those looking for leveraged, short-term opportunities. Each option has different features, fees and risk profiles, so understanding both can help you make the right choice. To help you choose, we offer a broker comparison further down this page.
Spot buying
A cash (spot) purchase means owning Ramsay Health Care shares directly—becoming a shareholder and potentially receiving dividends. Most Australian brokers charge a fixed commission per trade, typically around AU$5 to AU$15 per order.
Important example
If the Ramsay Health Care share price is AU$34.29, and you invest AU$1,000 (with an estimated AU$5 brokerage fee), you could buy about 29 shares.
Gain scenario:
If the share price rises by 10% (to AU$37.72), your investment would be worth about AU$1,100.
Result: That’s a +AU$100 gross gain—or +10% on your investment.
Trading via CFD
CFD (Contract for Difference) trading on Ramsay Health Care lets you speculate on price movements without actually owning the shares. This approach enables you to use leverage (borrowed funds) to amplify gains (and losses). CFD brokers typically charge through the spread (the difference between buy and sell prices) and may also apply overnight financing fees for positions held longer than a day.
Important example
Example: With AU$1,000 and 5x leverage, you control a AU$5,000 position on Ramsay shares.
Gain scenario:
If RHC’s price increases by 8%, your position gains 8% × 5 = 40%.
Result: You’d make AU$400 profit on your AU$1,000 stake (excluding fees).
Final advice
Before investing, carefully compare brokers’ fees, available features, and trading conditions—they can vary significantly and impact your net results. Your choice should align with your goals: spot buying for direct ownership, or CFDs for leveraged trading. For a detailed comparison of top brokers suitable for both methods, refer to the broker comparator featured further down the page.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions, including ASIC (Australia). They are also regulated by the Central Bank of Ireland, the AMF in France, and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions, including ASIC (Australia). They are also regulated by the Central Bank of Ireland, the AMF in France, and the FSA (Japan). Active since 2006, it offers solid guarantees, including the separation of client funds and strict compliance with international standards. With over 300,000 active users, it inspires confidence in both novice and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. Tutorials, demo accounts and free training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don't need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when you pay.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you're looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is a great choice.
Is IG reliable?
IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.
Why choose IG?
IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.
What are the fees at IG?
IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.
Who is IG for?
IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.
Is IG reliable?
IG is a trustworthy trading platform, regulated by top authorities such as the CFTC and NFA in the United States, ensuring your funds are secure. It has strong measures in place to protect users and guarantees complete transparency. Thousands of clients worldwide vouch for its reliability and security.
Why choose IG?
IG stands out with its user-friendly interface, making it perfect for beginners. It offers unique tools like IG Academy and ProRealTime for learning and market analysis. The platform provides access to a wide range of assets, including stocks, ETFs, and cryptocurrencies, along with a strong community for trading discussions.
What are the fees at IG?
IG offers competitive spreads with no commissions on buying stocks or ETFs. Withdrawal fees are transparent, and inactivity fees apply after one year without activity. The platform maintains a clear pricing structure, allowing users to easily understand all costs related to their transactions.
Who is IG for?
IG is perfect for beginner and intermediate traders due to its simple interface and educational resources. It also caters to experienced investors with advanced trading tools. Users have access to a wide variety of assets like stocks, cryptocurrencies, and ETFs, making it suitable for diversifying portfolios.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including ASIC (Australia). It is also regulated by the FCA (UK) and CySEC (Europe). With over 30 million users worldwide, eToro is widely recognised for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5 USD. In the event that you remain inactive for 12 months or more, a $10 USD monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).
Who is eToro for?
eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including ASIC (Australia). It is also regulated by the FCA (UK) and CySEC (Europe). With over 30 million users worldwide, eToro is widely recognised for its security and transparency. Based on our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don’t need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while investing.
You have access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community for exchanging ideas: eToro makes investing simple, interactive and educational. It's a bit like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of stocks or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposits are free, and withdrawals are set at $5 USD. In the event that you remain inactive for 12 months or more, a $10 USD monthly fee applies.
Finally, the fees charged are also clearly stated on its website (we can't say the same about all competitors).
Who is eToro for?
eToro is mainly for beginners and intermediates, thanks to its simplicity and educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Our 7 tips for buying Ramsay Health Care stock
| 📊 Step | 📝 Specific tip for Ramsay Health Care |
|---|---|
| Analyze the market | Assess demand trends in private healthcare, Australia’s ageing population, and Ramsay’s strong market position to understand the potential for sustained revenue growth. |
| Choose the right trading platform | Use an ASX-accredited trading platform with competitive brokerage fees and robust research tools suitable for investing in Ramsay Health Care shares. |
| Define your investment budget | Consider Ramsay’s share price volatility, high debt levels, and current yield to decide on an investment amount that fits your financial plan and risk appetite. |
| Choose a strategy (short or long term) | For most Australian investors, a long-term approach may suit Ramsay Health Care, given its ongoing strategic initiatives, global presence, and analyst projections for earnings growth. |
| Monitor news and financial results | Stay updated on Ramsay’s quarterly and annual reports, CEO commentary, and healthcare industry developments, as these can signal changes in profitability or sector trends. |
| Use risk management tools | Manage your risk by setting stop-loss levels, considering diversification, and regularly reviewing your position in Ramsay given its leverage and earnings variability. |
| Sell at the right time | Look to take profits or reduce exposure during price rallies—especially if technical indicators show overbought conditions—or if there is a deterioration in Ramsay’s financial health or outlook. |
The latest news about Ramsay Health Care
Ramsay Health Care stock has gained 1.81% in the last trading session, continuing a short-term upward trend. The current share price of AU$34.29 marks further distance from the 52-week low of AU$31.66, inspiring renewed interest in the company's valuation among Australian investors. Volume and price movement suggest growing momentum, with technical analysis confirming a buy signal across all simple moving averages from 5-day to 200-day, underscoring a positive market sentiment for Ramsay Health Care on the ASX.
Technical momentum indicators remain largely favourable, with analyst price targets supporting potential near-term upside for the share price. The Relative Strength Index (RSI) sits at 71.57, denoting strong buying interest but approaching overbought territory. The MACD and ADX indicate a clear, strong upward trend, bolstered by the 20-day, 50-day, and 100-day moving averages all sitting below the current price. Several market analysts have reaffirmed their 12-month average price target at AU$41.03, roughly 20% higher than current levels, citing anticipated earnings growth and improved operational performance, a positive signal for Australian institutional and retail investors evaluating entry points.
Ramsay Health Care's most recent half-year financial results highlight top-line resilience and a shift toward operational efficiency, despite sector headwinds. The company reported a 5.7% increase in half-year revenue to AU$8.54 billion, an important demonstration of market demand and pricing strength in Australian private healthcare. Strategic cost management initiatives—particularly in Ramsay’s extensive local hospital network—are underway to further protect margins. Though a non-recurring item negatively influenced net profit, management’s ongoing focus on efficiencies and technology-led improvements aims to drive future profitability across Australian operations.
The company’s decision to maintain its interim dividend at AU$0.40 per share reinforces confidence in cash flow and shareholder returns. Despite challenges from one-off expense items and margin compression, the board’s commitment to a stable 2.33% dividend yield is well received in Australia’s income-focused investment community. The announcement confirms management’s resolve to return value to shareholders and underpins Ramsay’s reputation for reliability among blue-chip healthcare stocks listed on the ASX, even as the company navigates a period of ongoing financial adjustment.
Appointment of new Group CEO Natalie Davis injects fresh leadership and signals evolving strategic direction for the Australian business. Natalie Davis’s commencement as CEO in October 2024 has been positively received, with market commentary emphasizing her healthcare sector expertise and track record in transformation. Early communication stresses her priorities in innovation, operational excellence, and patient experience—key areas that align with current Australian regulatory expectations and patient trends, and which are expected to drive medium-term growth for Ramsay’s extensive domestic hospital and clinic footprint.
FAQ
What is the latest dividend for Ramsay Health Care stock?
Ramsay Health Care currently pays a dividend. The most recent interim dividend was AU$0.40 per share. This payment took place after the company’s latest earnings, and the dividend yield stands at approximately 2.33%. Ramsay has maintained its dividend even amid financial challenges, though investors should note the very high payout ratio, which may affect future dividend sustainability.
What is the forecast for Ramsay Health Care stock in 2025, 2026, and 2027?
Based on the current price of AU$34.29, the projected end-of-year values are AU$44.58 for 2025, AU$51.44 for 2026, and AU$68.58 for 2027. Ramsay Health Care is benefiting from a stable revenue growth trajectory and renewed momentum driven by fresh leadership and ongoing healthcare demand across key markets. Many analysts expect continued sector strength to support further gains.
Should I sell my Ramsay Health Care shares?
Holding onto Ramsay Health Care shares could be a wise approach given the company’s strong international position and ongoing operational improvements. The current valuation and positive technical momentum suggest potential for recovery and future growth. With a leading share in private healthcare and continued investments in operational efficiency, Ramsay remains strategically resilient. For many investors, patience through temporary setbacks may pay off as the company works on improving margins and managing its debt.
How are dividends from Ramsay Health Care taxed for Australian investors?
Dividends from Ramsay Health Care are generally subject to Australian income tax. However, many of Ramsay’s dividends are franked, meaning they come with franking credits that can offset tax payable for eligible Australian residents. This can make dividend income from Ramsay particularly attractive for many local investors, as the credits help reduce double taxation. Always check the franked portion and your personal tax situation for optimal benefits.
What is the latest dividend for Ramsay Health Care stock?
Ramsay Health Care currently pays a dividend. The most recent interim dividend was AU$0.40 per share. This payment took place after the company’s latest earnings, and the dividend yield stands at approximately 2.33%. Ramsay has maintained its dividend even amid financial challenges, though investors should note the very high payout ratio, which may affect future dividend sustainability.
What is the forecast for Ramsay Health Care stock in 2025, 2026, and 2027?
Based on the current price of AU$34.29, the projected end-of-year values are AU$44.58 for 2025, AU$51.44 for 2026, and AU$68.58 for 2027. Ramsay Health Care is benefiting from a stable revenue growth trajectory and renewed momentum driven by fresh leadership and ongoing healthcare demand across key markets. Many analysts expect continued sector strength to support further gains.
Should I sell my Ramsay Health Care shares?
Holding onto Ramsay Health Care shares could be a wise approach given the company’s strong international position and ongoing operational improvements. The current valuation and positive technical momentum suggest potential for recovery and future growth. With a leading share in private healthcare and continued investments in operational efficiency, Ramsay remains strategically resilient. For many investors, patience through temporary setbacks may pay off as the company works on improving margins and managing its debt.
How are dividends from Ramsay Health Care taxed for Australian investors?
Dividends from Ramsay Health Care are generally subject to Australian income tax. However, many of Ramsay’s dividends are franked, meaning they come with franking credits that can offset tax payable for eligible Australian residents. This can make dividend income from Ramsay particularly attractive for many local investors, as the credits help reduce double taxation. Always check the franked portion and your personal tax situation for optimal benefits.
